Main > OPHTHALMOLOGY > Uveitis > Treatment > Co: USA. A. BioSimilar AdalimuMAb



Co: USA. A. BioSimilar AdalimuMAb's subsections
(*) EU Approval Date: ?
(*) JP Approval Date: 2016. 09.28.
(*) JP Licensee:
(*) USA Approval Date: 2016. 06.30
Company
Intermediate/Posterior/PanUveitis
Mechanism: TNF Inhibitor
Non Infectious Uveitis
Patent>Assignee; Claims; No.; Etc.
TradeMark
TradeMark Web-Site

Co: USA. A. BioSimilar AdalimuMAb's products
This section has no products